Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
VIBRANT: VIB4920 for Active Lupus Nephritis
NCT05201469 · View on ClinicalTrials.gov ↗
Study Summary
This is a multi-center double-blind placebo controlled clinical trial evaluating the efficacy of VIB4920 combined with mycophenolate mofetil (MMF) and prednisone in achieving a renal response in participants with active lupus nephritis (LN).
Conditions Studied
Interventions
- DRUG VIB4920
- DRUG Placebo for VIB4920
Study Locations (17)
California
- University of California San Diego School of Medicine: Division of Rheumatology, Allergy and Immunology — La Jolla
- UCLA Medical Center: Division of Rheumatology — Los Angeles
- of California, Irvine School of Medicine Division of Rheumatology — Orange
- University of California San Francisco School of Medicine: Lupus Clinic and Rheumatology Clinical Research Center — San Francisco
New York
- Feinstein Institute for Medical Research: Center for Autoimmune and Musculoskeletal Diseases — Manhasset
- Hospital for Special Surgery, New York: Division of Rheumatology — New York
- Columbia University Medical Center: Department of Medicine, Division of Rheumatology — New York
Pennsylvania
- Penn State Health Milton S. Hershey Medical Center: Division of Rheumatology — Hershey
- Temple University, Lewis Katz School of Medicine, Department of Medicine: Nephrology — Philadelphia
Colorado
- University of Colorado School of Medicine: Division of Rheumatology — Aurora
Connecticut
- Yale University School of Medicine: Section of Rheumatology — New Haven
Florida
- University of Miami Miller School of Medicine: Nephrology & Hypertension Division — Miami
Georgia
- Emory University School of Medicine: Division of Rheumatology — Atlanta
Illinois
- University of Chicago, Department of Medicine: Rheumatology — Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2022-05-16 |
| Est. Completion | 2027-03 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05201469
The ClinicalTrials.gov registry entry for NCT05201469 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 1,295 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Lupus Nephritis appearing as the primary indexed condition, and to 2 interventions — of which VIB4920 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05201469 reports 17 study locations spanning 11 distinct geographic areas — top geographies include California, New York, Pennsylvania. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05201469 about?
NCT05201469 is a clinical study titled "VIBRANT: VIB4920 for Active Lupus Nephritis". This is a multi-center double-blind placebo controlled clinical trial evaluating the efficacy of VIB4920 combined with mycophenolate mofetil (MMF) and prednisone in achieving a renal response in participants with active lupus nephritis (LN).
What is the current status of trial NCT05201469?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2022-05-16. Estimated completion is 2027-03.
What conditions does trial NCT05201469 study?
This clinical trial studies the following conditions: Lupus Nephritis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05201469?
The interventions under investigation include: VIB4920 (DRUG), Placebo for VIB4920 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05201469?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 1,295 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05201469 being conducted?
This trial has 17 study locations across California, Colorado, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.